ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS

Autor: Andrée-Anne Berthiaume, Sherif M. Reda, Kayla N. Kleist, Sharay E. Setti, Wei Wu, Jewel L. Johnston, Robert W. Taylor, Liana R. Stein, Hans J. Moebius, Kevin J. Church

Publikováno v: Frontiers in Neuroscience, Vol 18 (2024)

IntroductionAmyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disorder, primarily affects the motor neurons of the brain and spinal cord. Like other neurodegenerative conditions, ongoing pathological processes such as inc

Externí odkaz: https://doaj.org/article/a6b2579ccbb941feaef6cf0c8c0fe9a4

The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators

Autor: Hans J. Moebius, Kevin J. Church

Publikováno v: Journal of Alzheimer's Disease. 92:1-12

An estimated 6.5 million Americans aged 65 years or older have Alzheimer’s disease (AD), which will grow to 13.8 million Americans by 2060. Despite the growing burden of dementia, no fundamental change in drug development for AD has been seen in >

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5e3d38dd7be02341b5e95858e5beb83
https://doi.org/10.3233/jad-220871

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial

Autor: Xue, Hua, Kevin, Church, William, Walker, Philippe, L'Hostis, Geoffrey, Viardot, Philippe, Danjou, Suzanne, Hendrix, Hans J, Moebius

Publikováno v: Journal of Alzheimer's Disease. 86:1399-1413

Background: Fosgonimeton (ATH-1017) is being developed as a first-in-class regenerative therapy for people with Alzheimer’s disease (AD) and dementia; potentially improving dementia symptoms and altering disease progression by reversing synaptic di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d6bbe0cb6e5a7d2dcd40d048e2b45f4
https://doi.org/10.3233/jad-215511

ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer’s disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial

Autor: Hans J. Moebius, Charles B. Bernick, Paul Winner, Joyce Maalouf, Kai‐Bin Ooi, Samuel P. Dickson, Suzanne B. Hendrix, Kevin Church, John M. Olichney

Publikováno v: Alzheimer's & Dementia. 18

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c55e4465a6a375b688d4dae882e70682
https://doi.org/10.1002/alz.061572

Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial

Autor: Peter A. Ljubenkov, Mary Koestler, Florence Pasquier, Dana Hilt, Beth Ann Haynes, Renaud La Joie, Lauren Edwards, Bradley F. Boeve, Jacob Hesterman, Ira J. Goodman, Leonardo Iaccarino, Rik Vandenberghe, Catherine J. Mummery, Marco Onofrj, Sophie Auriacombe, Henry Riordan, Gerhard Koenig, Julio C. Rojas, Hans J Moebius, Adam L. Boxer, Giovanni B. Frisoni, Scott M. McGinnis, Gary Wisniewski, Ken Marek, Didier Hannequin, Murray Grossman, John C. van Swieten, Holger Patzke, Isabelle Le Ber, Baruch Harris, Barbara Borroni

Publikováno v: JAMA Network Open
JAMA Network Open, American Medical Association, 2021, 4 (9), pp.e2125584. ⟨10.1001/jamanetworkopen.2021.25584⟩
JAMA Network Open, 2021, 4 (9), pp.e2125584. ⟨10.1001/jamanetworkopen.2021.25584⟩
JAMA network open, 4(9):25584. American Medical Association

Key Points Question What is the safety, tolerability, pharmacodynamic, and pharmacokinetic profile of the histone deacetylase inhibitor FRM-0334 in participants with progranulin gene (GRN) haploinsufficiency? Findings In this randomized placebo-contr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85461c1fe333ce116f09c9a714feab20
http://hdl.handle.net/20.500.12278/123771